+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Hairy Cell Leukemia Therapeutics Market 2022-2026

  • PDF Icon

    Report

  • 120 Pages
  • June 2022
  • Region: Global
  • TechNavio
  • ID: 5606334
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the hairy cell leukemia therapeutics market and it is poised to grow by $ 177.85 mn during 2022-2026, accelerating at a CAGR of 6.7% during the forecast period. Our report on the hairy cell leukemia therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing exposure to hazardous substances leading to hairy cell leukemia, growing geriatric population, and strategic alliances.

The hairy cell leukemia therapeutics market analysis includes the product segment and geographic landscape.

The publisher's hairy cell leukemia therapeutics market is segmented as below:

By Product

  • Chemotherapy
  • Targeted therapy

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the increasing research grants for blood cancers as one of the prime reasons driving the hairy cell leukemia therapeutics market growth during the next few years. Also, advent of novel therapies and special drug designations will lead to sizable demand in the market.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on hairy cell leukemia therapeutics market covers the following areas:
  • Hairy cell leukemia therapeutics market sizing
  • Hairy cell leukemia therapeutics market forecast
  • Hairy cell leukemia therapeutics market industry analysis

The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hairy cell leukemia therapeutics market vendors that include AbbVie Inc., Amgen Inc., Astex Pharmaceuticals Inc., AstraZeneca Plc, Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Hikma Pharmaceuticals Plc, Innate Pharma SA, Merck KGaA, Pfizer Inc., and Viatris Inc. Also, the hairy cell leukemia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.

The publisher's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
  • Exhibit 06: Executive Summary - Chart on Incremental Growth
  • Exhibit 07: Executive Summary - Data Table on Incremental Growth
  • Exhibit 08: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape
  • 2.1 Market ecosystem
  • Exhibit 09: Parent market
  • Exhibit 10: Market Characteristics

3 Market Sizing
  • 3.1 Market definition
  • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021-2026
  • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis
  • 4.1 Five forces summary
  • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
  • 4.2 Bargaining power of buyers
  • Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
  • 4.3 Bargaining power of suppliers
  • Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
  • 4.4 Threat of new entrants
  • Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
  • 4.5 Threat of substitutes
  • Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
  • 4.6 Threat of rivalry
  • Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
  • 4.7 Market condition
  • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product
  • 5.1 Market segments
  • Exhibit 24: Chart on Product - Market share 2021-2026 (%)
  • Exhibit 25: Data Table on Product - Market share 2021-2026 (%)
  • 5.2 Comparison by Product
  • Exhibit 26: Chart on Comparison by Product
  • Exhibit 27: Data Table on Comparison by Product
  • 5.3 Chemotherapy - Market size and forecast 2021-2026
  • Exhibit 28: Chart on Chemotherapy - Market size and forecast 2021-2026 ($ million)
  • Exhibit 29: Data Table on Chemotherapy - Market size and forecast 2021-2026 ($ million)
  • Exhibit 30: Chart on Chemotherapy - Year-over-year growth 2021-2026 (%)
  • Exhibit 31: Data Table on Chemotherapy - Year-over-year growth 2021-2026 (%)
  • 5.4 Targeted therapy - Market size and forecast 2021-2026
  • Exhibit 32: Chart on Targeted therapy - Market size and forecast 2021-2026 ($ million)
  • Exhibit 33: Data Table on Targeted therapy - Market size and forecast 2021-2026 ($ million)
  • Exhibit 34: Chart on Targeted therapy - Year-over-year growth 2021-2026 (%)
  • Exhibit 35: Data Table on Targeted therapy - Year-over-year growth 2021-2026 (%)
  • 5.5 Market opportunity by Product
  • Exhibit 36: Market opportunity by Product ($ million)

6 Customer Landscape
  • 6.1 Customer landscape overview
  • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape
  • 7.1 Geographic segmentation
  • Exhibit 38: Chart on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibit 39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
  • 7.2 Geographic comparison
  • Exhibit 40: Chart on Geographic comparison
  • Exhibit 41: Data Table on Geographic comparison
  • 7.3 North America - Market size and forecast 2021-2026
  • Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
  • Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
  • 7.4 Europe - Market size and forecast 2021-2026
  • Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
  • 7.5 Asia - Market size and forecast 2021-2026
  • Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
  • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
  • Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • 7.7 US - Market size and forecast 2021-2026
  • Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
  • Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
  • Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
  • Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
  • 7.8 Germany - Market size and forecast 2021-2026
  • Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
  • Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
  • Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
  • Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
  • 7.9 China - Market size and forecast 2021-2026
  • Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
  • Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
  • Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
  • Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)
  • 7.10 Canada - Market size and forecast 2021-2026
  • Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
  • 7.11 India - Market size and forecast 2021-2026
  • Exhibit 74: Chart on India - Market size and forecast 2021-2026 ($ million)
  • Exhibit 75: Data Table on India - Market size and forecast 2021-2026 ($ million)
  • Exhibit 76: Chart on India - Year-over-year growth 2021-2026 (%)
  • Exhibit 77: Data Table on India - Year-over-year growth 2021-2026 (%)
  • 7.12 Market opportunity By Geographical Landscape
  • Exhibit 78: Market opportunity By Geographical Landscape ($ million)

8 Drivers, Challenges, and Trends
  • 8.1 Market drivers
  • 8.2 Market challenges
  • 8.3 Impact of drivers and challenges
  • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
  • 8.4 Market trends

9 Vendor Landscape
  • 9.1 Overview
  • 9.2 Vendor landscape
  • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
  • 9.3 Landscape disruption
  • Exhibit 81: Overview on factors of disruption
  • 9.4 Industry risks
  • Exhibit 82: Impact of key risks on business

10 Vendor Analysis
  • 10.1 Vendors covered
  • Exhibit 83: Vendors covered
  • 10.2 Market positioning of vendors
  • Exhibit 84: Matrix on vendor position and classification
  • 10.3 AbbVie Inc.
  • Exhibit 85: AbbVie Inc. - Overview
  • Exhibit 86: AbbVie Inc. - Product / Service
  • Exhibit 87: AbbVie Inc. - Key offerings
  • 10.4 Amgen Inc.
  • Exhibit 88: Amgen Inc. - Overview
  • Exhibit 89: Amgen Inc. - Product / Service
  • Exhibit 90: Amgen Inc. - Key offerings
  • 10.5 AstraZeneca Plc
  • Exhibit 91: AstraZeneca Plc - Overview
  • Exhibit 92: AstraZeneca Plc - Product / Service
  • Exhibit 93: AstraZeneca Plc - Key news
  • Exhibit 94: AstraZeneca Plc - Key offerings
  • 10.6 F. Hoffmann La Roche Ltd.
  • Exhibit 95: F. Hoffmann La Roche Ltd. - Overview
  • Exhibit 96: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibit 97: F. Hoffmann La Roche Ltd. - Key news
  • Exhibit 98: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibit 99: F. Hoffmann La Roche Ltd. - Segment focus
  • 10.7 Fresenius SE and Co. KGaA
  • Exhibit 100: Fresenius SE and Co. KGaA - Overview
  • Exhibit 101: Fresenius SE and Co. KGaA - Business segments
  • Exhibit 102: Fresenius SE and Co. KGaA - Key news
  • Exhibit 103: Fresenius SE and Co. KGaA - Key offerings
  • Exhibit 104: Fresenius SE and Co. KGaA - Segment focus
  • 10.8 Hikma Pharmaceuticals Plc
  • Exhibit 105: Hikma Pharmaceuticals Plc - Overview
  • Exhibit 106: Hikma Pharmaceuticals Plc - Business segments
  • Exhibit 107: Hikma Pharmaceuticals Plc - Key offerings
  • Exhibit 108: Hikma Pharmaceuticals Plc - Segment focus
  • 10.9 Innate Pharma SA
  • Exhibit 109: Innate Pharma SA - Overview
  • Exhibit 110: Innate Pharma SA - Product / Service
  • Exhibit 111: Innate Pharma SA - Key offerings
  • 10.10 Merck KGaA
  • Exhibit 112: Merck KGaA - Overview
  • Exhibit 113: Merck KGaA - Business segments
  • Exhibit 114: Merck KGaA - Key news
  • Exhibit 115: Merck KGaA - Key offerings
  • Exhibit 116: Merck KGaA - Segment focus
  • 10.11 Pfizer Inc.
  • Exhibit 117: Pfizer Inc. - Overview
  • Exhibit 118: Pfizer Inc. - Product / Service
  • Exhibit 119: Pfizer Inc. - Key news
  • Exhibit 120: Pfizer Inc. - Key offerings
  • 10.12 Viatris Inc.
  • Exhibit 121: Viatris Inc. - Overview
  • Exhibit 122: Viatris Inc. - Business segments
  • Exhibit 123: Viatris Inc. - Key offerings
  • Exhibit 124: Viatris Inc. - Segment focus

11 Appendix
  • 11.1 Scope of the report
  • 11.2 Inclusions and exclusions checklist
  • Exhibit 125: Inclusions checklist
  • Exhibit 126: Exclusions checklist
  • 11.3 Currency conversion rates for US$
  • Exhibit 127: Currency conversion rates for US$
  • 11.4 Research methodology
  • Exhibit 128: Research methodology
  • Exhibit 129: Validation techniques employed for market sizing
  • Exhibit 130: Information sources
  • 11.5 List of abbreviations
  • Exhibit 131: List of abbreviations

Exhibits:
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Product
Exhibits 6: Executive Summary - Chart on Incremental Growth
Exhibits 7: Executive Summary - Data Table on Incremental Growth
Exhibits 8: Executive Summary - Chart on Vendor Market Positioning
Exhibits 9: Parent market
Exhibits 10: Market Characteristics
Exhibits 11: Offerings of vendors included in the market definition
Exhibits 12: Market segments
Exhibits 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibits 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibits 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits 17: Five forces analysis - Comparison between 2021 and 2026
Exhibits 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
Exhibits 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
Exhibits 20: Threat of new entrants - Impact of key factors in 2021 and 2026
Exhibits 21: Threat of substitutes - Impact of key factors in 2021 and 2026
Exhibits 22: Threat of rivalry - Impact of key factors in 2021 and 2026
Exhibits 23: Chart on Market condition - Five forces 2021 and 2026
Exhibits 24: Chart on Product - Market share 2021-2026 (%)
Exhibits 25: Data Table on Product - Market share 2021-2026 (%)
Exhibits 26: Chart on Comparison by Product
Exhibits 27: Data Table on Comparison by Product
Exhibits 28: Chart on Chemotherapy - Market size and forecast 2021-2026 ($ million)
Exhibits 29: Data Table on Chemotherapy - Market size and forecast 2021-2026 ($ million)
Exhibits 30: Chart on Chemotherapy - Year-over-year growth 2021-2026 (%)
Exhibits 31: Data Table on Chemotherapy - Year-over-year growth 2021-2026 (%)
Exhibits 32: Chart on Targeted therapy - Market size and forecast 2021-2026 ($ million)
Exhibits 33: Data Table on Targeted therapy - Market size and forecast 2021-2026 ($ million)
Exhibits 34: Chart on Targeted therapy - Year-over-year growth 2021-2026 (%)
Exhibits 35: Data Table on Targeted therapy - Year-over-year growth 2021-2026 (%)
Exhibits 36: Market opportunity by Product ($ million)
Exhibits 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 38: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibits 39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
Exhibits 40: Chart on Geographic comparison
Exhibits 41: Data Table on Geographic comparison
Exhibits 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibits 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibits 44: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibits 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
Exhibits 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibits 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibits 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibits 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
Exhibits 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibits 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibits 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibits 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
Exhibits 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibits 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibits 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibits 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibits 58: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibits 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibits 60: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibits 61: Data Table on US - Year-over-year growth 2021-2026 (%)
Exhibits 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibits 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibits 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibits 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
Exhibits 66: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibits 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibits 68: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibits 69: Data Table on China - Year-over-year growth 2021-2026 (%)
Exhibits 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibits 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibits 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibits 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
Exhibits 74: Chart on India - Market size and forecast 2021-2026 ($ million)
Exhibits 75: Data Table on India - Market size and forecast 2021-2026 ($ million)
Exhibits 76: Chart on India - Year-over-year growth 2021-2026 (%)
Exhibits 77: Data Table on India - Year-over-year growth 2021-2026 (%)
Exhibits 78: Market opportunity By Geographical Landscape ($ million)
Exhibits 79: Impact of drivers and challenges in 2021 and 2026
Exhibits 80: Overview on Criticality of inputs and Factors of differentiation
Exhibits 81: Overview on factors of disruption
Exhibits 82: Impact of key risks on business
Exhibits 83: Vendors covered
Exhibits 84: Matrix on vendor position and classification
Exhibits 85: AbbVie Inc. - Overview
Exhibits 86: AbbVie Inc. - Product / Service
Exhibits 87: AbbVie Inc. - Key offerings
Exhibits 88: Amgen Inc. - Overview
Exhibits 89: Amgen Inc. - Product / Service
Exhibits 90: Amgen Inc. - Key offerings
Exhibits 91: AstraZeneca Plc - Overview
Exhibits 92: AstraZeneca Plc - Product / Service
Exhibits 93: AstraZeneca Plc - Key news
Exhibits 94: AstraZeneca Plc - Key offerings
Exhibits 95: F. Hoffmann La Roche Ltd. - Overview
Exhibits 96: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 97: F. Hoffmann La Roche Ltd. - Key news
Exhibits 98: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 99: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 100: Fresenius SE and Co. KGaA - Overview
Exhibits 101: Fresenius SE and Co. KGaA - Business segments
Exhibits 102: Fresenius SE and Co. KGaA - Key news
Exhibits 103: Fresenius SE and Co. KGaA - Key offerings
Exhibits 104: Fresenius SE and Co. KGaA - Segment focus
Exhibits 105: Hikma Pharmaceuticals Plc - Overview
Exhibits 106: Hikma Pharmaceuticals Plc - Business segments
Exhibits 107: Hikma Pharmaceuticals Plc - Key offerings
Exhibits 108: Hikma Pharmaceuticals Plc - Segment focus
Exhibits 109: Innate Pharma SA - Overview
Exhibits 110: Innate Pharma SA - Product / Service
Exhibits 111: Innate Pharma SA - Key offerings
Exhibits 112: Merck KGaA - Overview
Exhibits 113: Merck KGaA - Business segments
Exhibits 114: Merck KGaA - Key news
Exhibits 115: Merck KGaA - Key offerings
Exhibits 116: Merck KGaA - Segment focus
Exhibits 117: Pfizer Inc. - Overview
Exhibits 118: Pfizer Inc. - Product / Service
Exhibits 119: Pfizer Inc. - Key news
Exhibits 120: Pfizer Inc. - Key offerings
Exhibits 121: Viatris Inc. - Overview
Exhibits 122: Viatris Inc. - Business segments
Exhibits 123: Viatris Inc. - Key offerings
Exhibits 124: Viatris Inc. - Segment focus
Exhibits 125: Inclusions checklist
Exhibits 126: Exclusions checklist
Exhibits 127: Currency conversion rates for US$
Exhibits 128: Research methodology
Exhibits 129: Validation techniques employed for market sizing
Exhibits 130: Information sources
Exhibits 131: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global hairy cell leukemia therapeutics market: AbbVie Inc., Amgen Inc., Astex Pharmaceuticals Inc., AstraZeneca Plc, Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Hikma Pharmaceuticals Plc, Innate Pharma SA, Merck KGaA, Pfizer Inc., and Viatris Inc.

Commenting on the report, an analyst from the publisher said: "The latest trend gaining momentum in the market is increasing research grants for blood cancers."

According to the report, one of the major drivers for this market is the increasing exposure to hazardous substances leading to hairy cell leukemia.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.

The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.


Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbvie Inc.
  • Amgen Inc.
  • Astex Pharmaceuticals Inc.
  • Astrazeneca plc
  • Dr. Reddys Laboratories Ltd.
  • F. Hoffmann La Roche Ltd.
  • Fresenius Se and Co. Kgaa
  • Hikma Pharmaceuticals plc
  • Innate Pharma Sa
  • Merck Kgaa
  • Pfizer Inc.
  • Viatris Inc.